Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $101 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $101.
December 14, 2023 | 5:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst maintains an Overweight rating and a $101 price target for Intra-Cellular Therapies.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst like Charles Duncan could lead to increased investor confidence in Intra-Cellular Therapies, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100